Meet Calibr-Skaggs and Scripps Research
Calibr-SKAGGS and CLF065: Working Together to Help People with Chronic Pouchitis
What Is Calibr-Skaggs?
The Calibr-Skaggs Institute for Innovative Medicines (Calibr-Skaggs) is the drug development division of Scripps Research. It’s a team of scientists who focus on turning lab discoveries into real medicines that can help people. They focus on diseases that don’t have enough treatment options—like chronic pouchitis.
What Is CLF065?
CLF065 is a new investigational treatment that Calibr-Skaggs created. It’s made to help people with chronic pouchitis, a type of ongoing inflammation in the pouch after J-pouch surgery.
CLF065 is based on a natural hormone in the body called GLP-2. This hormone helps the intestines heal. Calibr-Skaggs made a long-lasting version of it so the medicine can work longer with fewer doses. The goal is to help the pouch heal by strengthening the intestinal lining, which may also reduce inflammation and improve symptoms like urgency, cramping, and fatigue.
How Calibr-Skaggs and Scripps Research Work Together
Calibr-Skaggs and Scripps Research work as a team. Scripps Research finds new ideas and discoveries in the lab. Calibr-Skaggs turns those ideas into treatments—like CLF065—that can be tested in clinical trials.
To run clinical trials like this one, Calibr-Skaggs partners with hospitals, research institutions, and healthcare organizations to ensure the study is conducted safely and effectively.
Thanks to this collaboration, people with chronic pouchitis now have a chance to explore a new investigational product when other options haven’t worked.